This suggests that melanoma MAPKi-resistant cells may mediate the weakening of antigen presentation and the reduction of T cells by inhibiting the expression of MHC-I molecules, resulting in resistance to anti-PD-1/PD-L1 immunotherapy. This evidence concerns the gene CD274 and melanoma.